{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T14:43:02Z","timestamp":1760366582917,"version":"build-2065373602"},"reference-count":11,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2022,1,5]],"date-time":"2022-01-05T00:00:00Z","timestamp":1641340800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxins"],"abstract":"<jats:p>Over the past 30 years, botulinum toxin (BoNT) has seen an ever-expanding use in disorders afflicting the nervous system [...]<\/jats:p>","DOI":"10.3390\/toxins14010041","type":"journal-article","created":{"date-parts":[[2022,1,9]],"date-time":"2022-01-09T23:35:09Z","timestamp":1641771309000},"page":"41","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Editorial on the Special Issue \u201cBotulinum Toxin for the Treatment of Neurological Disorders: Where We Are and Where We Need to Go\u201d"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7513-8651","authenticated-orcid":false,"given":"Mandar","family":"Jog","sequence":"first","affiliation":[{"name":"Department of Clinical Neurological Sciences, London Health Sciences Centre\u2014Lawson Health Research Institute, 339 Windermere Road, A10-026, London, ON N6A 5A5, Canada"},{"name":"Schulich School of Medicine and Dentistry, University of Western, 1151 Richmond Street, London, ON N6A 3K7, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5346-0180","authenticated-orcid":false,"given":"Alfonso","family":"Fasano","sequence":"additional","affiliation":[{"name":"Movement Disorders Center, Toronto Western Hospital, University of Toronto, Toronto, ON M5T 2S8, Canada"},{"name":"Krembil Brain Institute, Toronto, ON M5T 2S8, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,1,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Fasano, A., Paramanandam, V., and Jog, M. (2020). Use of AbobotulinumtoxinA in Adults with Cervical Dystonia: A Systematic Literature Review. Toxins, 12.","DOI":"10.3390\/toxins12080470"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Fietzek, U.M., Nene, D., Schramm, A., Appel-Cresswell, S., Kosutzka, Z., Walter, U., Wissel, J., Berweck, S., Chouinard, S., and Baumer, T. (2021). The Role of Ultrasound for the Personalized Botulinum Toxin Treatment of Cervical Dystonia. Toxins, 13.","DOI":"10.3390\/toxins13050365"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Gorodetsky, C., Azevedo, P., Candeias da Silva, C., and Fasano, A. (2021). Factors Influencing the Surgical Decision in Dystonia Patients Referred for Deep Brain Stimulation. Toxins, 13.","DOI":"10.3390\/toxins13080511"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Ganguly, J., Kulshreshtha, D., Almotiri, M., and Jog, M. (2021). Muscle Tone Physiology and Abnormalities. Toxins, 13.","DOI":"10.3390\/toxins13040282"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Hefter, H., Nickels, W., Rosenthal, D., Samadzadeh, S., and Albrecht, P. (2021). Continuous Increase of Efficacy under Repetitive Injections of Botulinum Toxin Type\/A beyond the First Treatment for Adult Spastic Foot Drop. Toxins, 13.","DOI":"10.3390\/toxins13070466"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Isaacson, J., Patel, S., Torres-Yaghi, Y., and Pagan, F. (2020). Sialorrhea in Parkinson\u2019s Disease. Toxins, 12.","DOI":"10.3390\/toxins12110691"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Becker, W.J. (2020). Botulinum Toxin in the Treatment of Headache. Toxins, 12.","DOI":"10.3390\/toxins12120803"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Dominguez Vivero, C., Leira, Y., Saavedra Pineiro, M., Rodriguez-Osorio, X., Ramos-Cabrer, P., Villalba Martin, C., Sobrino, T., Campos, F., Castillo, J., and Leira, R. (2020). Iron Deposits in Periaqueductal Gray Matter Are Associated with Poor Response to OnabotulinumtoxinA in Chronic Migraine. Toxins, 12.","DOI":"10.3390\/toxins12080479"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Jog, M., Lee, J., Scheschonka, A., Chen, R., Ismail, F., Boulias, C., Hobson, D., King, D., Althaus, M., and Simon, O. (2020). Tolerability and Efficacy of Customized IncobotulinumtoxinA Injections for Essential Tremor: A Randomized, Double-Blind, Placebo-Controlled Study. Toxins, 12.","DOI":"10.3390\/toxins12120807"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Samotus, O., Lee, J., and Jog, M. (2021). Developing a Consistent, Reproducible Botulinum Toxin Type A Dosing Method for Upper Limb Tremor by Kinematic Analysis. Toxins, 13.","DOI":"10.3390\/toxins13040264"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Choudhury, S., Baker, M.R., Chatterjee, S., and Kumar, H. (2021). Botulinum Toxin: An Update on Pharmacology and Newer Products in Development. Toxins, 13.","DOI":"10.3390\/toxins13010058"}],"container-title":["Toxins"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6651\/14\/1\/41\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T14:00:23Z","timestamp":1760364023000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6651\/14\/1\/41"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,5]]},"references-count":11,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1]]}},"alternative-id":["toxins14010041"],"URL":"https:\/\/doi.org\/10.3390\/toxins14010041","relation":{},"ISSN":["2072-6651"],"issn-type":[{"type":"electronic","value":"2072-6651"}],"subject":[],"published":{"date-parts":[[2022,1,5]]}}}